Hana Ventures
VC Fund
Seoul, South Korea
Hana Ventures is a corporate venture capital of Hana Financial Group.
- Total investments:
- 256
- Last investment:
- Lead investor:
- 16%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Hana Ventures invests in
Stages Hana Ventures invests in
Countries Hana Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $273k–$4.4M
- Series A
- $1.6M–$13M
- Venture - Series Unknown
- $882k–$11M
Investment Focus
Industry
- Software 26 (10%)
- Artificial Intelligence 21 (8%)
- Health Care 20 (8%)
- Manufacturing 20 (8%)
- Biotechnology 16 (6%)
Stage
- Seed 55 (21%)
- Series A 54 (21%)
- Venture - Series Unknown 52 (20%)
- Series B 41 (16%)
- Series C 14 (5%)
Country
- South Korea 168 (66%)
- United States 4 (2%)
- Indonesia 2 (1%)
- Peru 1 (0%)
- India 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Jae-Kwon Jeon
CEO
|
CEO | Total investments: 1 | Find email | |
Kanghoon Lee
Principal
|
Principal | Total investments: 4 | Find email | |
|
Kang Hoon-mo
Executive director
|
Executive director | Total investments: 9 | Find email | |
|
Kim Hyun joon
Chief
|
Chief | Total investments: 2 | Find email | |
Kim Seong-gon
Venture Capitalist
|
Venture Capitalist | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Linq
|
We are creating ‘hyper-automated insurance platforms’ to comprehensively support underwriters and claim adjusters and to facilitate communication between insurers and reinsurers using AI and deep learning. | $22M / Series A / Jul 02, 2026 | |
Solivis
|
Solivis is the manufacturer of solid-state batteries designed for next-generation battery packs. The company's product is used as a secondary battery for electric vehicles and has developed a wet synthesis method that can mass-produce a sulfide-based solid electrolyte with homogeneous high ionic conductivity, enabling clients to significantlyimprove productivity by reducing process costs and shortening the synthesis time. | $13.7M / Series C / Jun 04, 2026 | |
Unastella
|
Unastella is an aerospace company developing human spaceflight technologies, including launch vehicles and suborbital tourism systems. The company focuses on advancing reusable rocket technology and future space travel infrastructure for civilian space exploration missions. Unastella aims to support the growth of private human spaceflight andnext-generation aerospace innovation. | $22.2M / Series B / Jun 01, 2026 | |
Featuring
|
Featuring’s goal is to make it easy for anyone to see and utilize the power of influencers. Today, as companies are accelerating their transition to digital business due to COVID-19, the number of companies leveraging The number of influencers is explosively increasing. Featuring allows brands and marketers to discover product-fit influencers andhelps matching based on their needs. Currently, over 3,600 brands are using Featuring, and more than 8,500 influencer campaigns have been done. As a Korea-based startup, Featuring plans on expanding the business to Far East Asia, including Japan and China. | $10.2M / Series B / May 19, 2026 | |
WIRobotics
|
WIRobotics is a Wearable robot that lessen physical demands on your body to safely allow active motion. | $63.5M / Series B / May 15, 2026 | |
Protier Biotech
|
PROTIER Biotech is a company leading the development of therapeutics through innovative biotechnology . | $2.3M / Seed / Apr 06, 2026 | |
Mediwhale
|
Medi Whale seeks to achieve sustainable healthcare where every eye can truly be the window to one’s health with our world's first-of-its-kind 1-stop AI screening platform solution for cardiovascular, renal, metabolic risk assessment, and eye disease diagnosis. Our AI Platform was developed through several clinical collaborations (Korea,Singapore, India, UK, and other European datasets) using structured longitudinal event-based datasets for the development of our retinal biomarker engines. RetiCVD® (cardiovascular disease risk assessment): Developed using coronary artery calcium (CAC) score, CAC is recognized as the gold standard for precise CVD risk calculation. Our CVD engine predicts the presence of CAC and provides a stratified probabilistic risk based on US ASCVD and EU SCORE guidelines.RetiCKD® (chronic kidney disease risk assessment): Developed using eGFR and full lab panel, our CKD engine has been demonstrated to achieve better predictive capability as compared to eGFR or full panel analysis.RetiEYE®: Referable Eye Disease engine detects and flags common aging-related eye modalities such as diabetic retinopathy, age-related macular degeneration, glaucoma, and cataract at its referable disease state.Medi Whale retinal-based systemic biomarkers have been clinically demonstrated to be non-inferior to current gold standards and are recognized by clinical and scientific communities with two Lancet Digital Health publications. | $13.3M / Series C / Mar 27, 2026 | |
ActionPower
|
ActionPower is an AI-based startup company that offers speech recognition and natural language processing technology services. | $4.1M / Series B / Mar 05, 2026 | |
Refilled
|
Refilled offers tailored hair loss home care services based on scientific hair loss study findings. The company's products specialize in two patented ingredients, which are nucleic acid proteins that are responsible for signaling between cells, not nutrients that supply nutrients to the scalp and hair, enabling customers to strengthen hairfollicles and enhance growth. | $7.5M / Venture - Series Unknown / Mar 03, 2026 | |
Sasung power
|
Sasung power enhances energy storage performance using advanced structural battery source technology, developing new batteries for structural support and eco-friendly lightweight structures. | $1M / Series A / Feb 23, 2026 | |
| See all 256 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Hana Ventures invest in?
Hana Ventures invests primarily in Software, Artificial Intelligence and Health Care startups, most often at Seed and Series A stage. Most of the 256 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Hana Ventures's check size?
Hana Ventures typically joins rounds of $273k–$4.4M at Seed, $1.6M–$13M at Series A and $882k–$11M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Hana Ventures participates in.
How do I contact Hana Ventures?
Public channels for Hana Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Hana Ventures?
The team at Hana Ventures includes Jae-Kwon Jeon (CEO), Kanghoon Lee (Principal) and Kang Hoon-mo (Executive director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
